Why Is Sinemet So Hard to Find? [Explained for 2026]

If you or a loved one depends on Sinemet (carbidopa/levodopa) to manage Parkinson's disease, you've likely run into the same wall: you arrive at the pharmacy and it's out of stock. Nobody can tell you when it will be back. And every phone call leads to another dead end.

You are not imagining it. Sinemet and its generic equivalent, carbidopa/levodopa, have been plagued by shortages for years—and in 2026, specific formulations remain in active shortage. Here is exactly what is happening and why.

What Exactly Is Sinemet?

Sinemet is a brand-name combination of two drugs—carbidopa and levodopa—that has been the gold-standard treatment for Parkinson's disease for decades. Levodopa is converted to dopamine in the brain, replacing the dopamine that Parkinson's disease destroys. Carbidopa acts as a shield, preventing levodopa from breaking down before it reaches the brain. This combination means patients need less levodopa overall, which reduces nausea and side effects.

The brand-name Sinemet (manufactured by Merck) has actually been discontinued. Patients today are almost always dispensed generic carbidopa/levodopa. The extended-release version, Sinemet CR, was also discontinued by Merck in 2019–2020. That discontinuation set the stage for the supply problems that continue today.

Which Formulations Are Actually in Shortage in 2026?

Not all forms of carbidopa/levodopa are equally affected. Here is the breakdown as of 2026:

Immediate-release (IR) tablets: Generally available from multiple generic manufacturers (Teva, Amneal, Sun Pharma, and others). Spot shortages still occur at specific pharmacies but overall supply is relatively stable.

Extended-release (ER/CR) tablets: This is the hardest-hit formulation. As of early 2026, carbidopa/levodopa ER tablets remain on the American Society of Health-System Pharmacists (ASHP) drug shortage list. Accord Healthcare discontinued the 25/100 mg ER strength; only the 50/200 mg ER remains from that manufacturer.

Orally disintegrating tablets (ODT): Effectively discontinued. Both Viatris (2021) and Sun Pharma (December 2022) stopped making this formulation.

Brand ER capsules (Rytary, Crexont): Available but significantly more expensive and often requiring prior authorization.

Why Did the Shortage Start in the First Place?

The Sinemet shortage is the product of several overlapping forces that have built up over years:

1. Manufacturer Consolidation and Discontinuations

When Merck exited the Sinemet CR market in 2019–2020, the entire extended-release supply shifted to a small number of generic manufacturers. That left very little redundancy in the supply chain. When even one of those manufacturers has a quality issue, a manufacturing delay, or discontinues a strength, patients feel it immediately. Accord Healthcare's decision to stop making 25/100 mg ER tablets is a recent example of exactly this problem.

2. The Drug Is Inexpensive—Which Sounds Good But Isn't

Generic carbidopa/levodopa IR tablets can cost as little as $9 per month with a GoodRx coupon. That is great news for patients but it means manufacturers have very thin profit margins. Low-margin drugs are the first to be deprioritized when a manufacturer needs to allocate factory capacity. There is simply little financial incentive to invest heavily in production of a drug that earns little per unit.

3. The 'Eight Tablet Limit' Creates Extra Barriers

There is a separate but related barrier for many patients: the so-called "eight Sinemet limit." Some pharmacies and insurance companies cite the original FDA labeling language and automatically flag or reject prescriptions for more than eight tablets per day. This is not a safety ceiling—many patients with advanced Parkinson's disease require higher daily doses—but it adds another layer of frustration on top of the actual availability problem.

4. Demand Is Growing Steadily

The number of Americans living with Parkinson's disease is growing as the population ages. More patients means more demand for the same drug, tightening supply further. Unlike some shortage drugs that affect a relatively small population, carbidopa/levodopa is used by hundreds of thousands of patients in the United States.

What Can Patients Do Right Now?

Finding Sinemet (carbidopa/levodopa) in stock requires strategy in 2026:

Call multiple pharmacies: Availability varies significantly from one pharmacy to the next, even within the same chain.

Use medfinder: medfinder calls pharmacies near you to check which ones have your medication in stock, so you don't have to do the legwork yourself.

Ask your neurologist about formulation options: If ER tablets are unavailable, IR tablets dosed more frequently may be a workable bridge. Newer ER capsule options like Crexont (approved 2024) may also be accessible.

Never stop abruptly: Stopping carbidopa/levodopa suddenly can trigger serious withdrawal effects including high fever, muscle rigidity, and confusion. Contact your doctor immediately if you cannot fill your prescription.

Is the Shortage Expected to Improve?

The FDA is aware of the shortage and continues to work with manufacturers to increase supply. The entry of additional generic manufacturers into the ER tablet market could help ease availability, but FDA approval timelines for generics are unpredictable. For the immediate-release formulation, supply is generally more stable—but that can change based on manufacturing disruptions. No confirmed resolution date has been announced for the ER tablet shortage as of early 2026.

For more help, read our guide on how to find Sinemet in stock near you and the latest Sinemet shortage update for 2026.